AstraZeneca PLC (AZN)vsTeck Resources Ltd Class B (TECK)
AZN
AstraZeneca PLC
$185.78
+0.93%
HEALTHCARE · Cap: $284.63B
TECK
Teck Resources Ltd Class B
$50.36
+3.71%
BASIC MATERIALS · Cap: $23.82B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 446% more annual revenue ($58.74B vs $10.76B). AZN leads profitability with a 17.4% profit margin vs 13.0%. TECK appears more attractively valued with a PEG of 0.96. TECK earns a higher WallStSmart Score of 73/100 (B).
AZN
Strong Buy66
out of 100
Grade: B-
TECK
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.8%
Fair Value
$306.07
Current Price
$185.78
$120.29 discount
Margin of Safety
+37.4%
Fair Value
$96.41
Current Price
$50.36
$46.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 32.6%
Growing faster than its price suggests
Earnings expanding 42.5% YoY
Areas to Watch
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Grey zone — moderate risk
ROE of 4.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : TECK
The strongest argument for TECK centers on Price/Book, Operating Margin, PEG Ratio. PEG of 0.96 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.
Bear Case : TECK
The primary concerns for TECK are Altman Z-Score, Return on Equity.
Key Dynamics to Monitor
TECK carries more volatility with a beta of 1.53 — expect wider price swings.
TECK is growing revenue faster at 9.8% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TECK scores higher overall (73/100 vs 66/100). AZN offers better value entry with a 32.8% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Teck Resources Ltd Class B
BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA
Teck Resources Limited is dedicated to exploring, acquiring, developing and producing natural resources in Asia, Europe and North America. The company is headquartered in Vancouver, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?